Itraconazole Loaded Nano structured lipid Carriers based In-situ Gel: Formulation, Optimization, Ex-Vivo Permeation and In-vitro Anti-Fungal Activity

Abstract

The current study aimed to design and mark Nanostructured lipid carriers (NLCs) combined with Itraconazole for topical fungal activity. Itraconazole is a broad-based antifungal agent derived from azole that has an anti-fungal, yeast, fungus, and dermatophytes-based action on cell membrane disruption. Itraconazole-NLCs were developed using the high-density homogenization method Oleic acid as a liquid lipid, Glyceryl monostearate as a solid lipid, and Poloxamer 188 as a surfactant. Advanced Itraconazole-NLC is targeted at a wide range of pharmaceutical parameters including particle size, Entrapment efficiency, drug content, and compound drug release. A separate Calorimetry (DSC) study was performed on NLCs to detect changes in drug and lipid conversion. In vitro, drug release studies have been found to vary widely and the % CDR have values b / w 55.37 ± 2.26 - 92.54 ± 1.18% depending on the type of polymer and the particle size. Exfoliation of Ex-vivo skin and Pharmacodynamic studies have shown that Itraconazole-loaded NLCs have better penetration potential than commercially available compounds and are able to reduce fungal infections to a large extent. In-vitro antifungal activity shows that itraconazole-NLCs were effective in reducing the growth of Candida Albicans. Therefore, the study concludes that Itraconazole-loaded NLCs have a persistent release profile and have the potential for the treatment of fungal topical infections.